Celexion is a bioengineering company that develops powerful platform technologies and products for partners in the pharmaceutical, industrial, agricultural, and consumer sectors. The company’s technologies include the SECANT platform for engineering high performance protein products, a library of human antibodies for therapeutic lead generation, enzymatic pathways for synthesis of a variety of high-value chemicals and materials from wastes and other inexpensive precursors, and a novel family of enzymes for manipulation of chromosome-sized DNA. Celexion is a Flagship VentureLabs™ company.  

Noubar Afeyan, Harry Wilcox and Brian Baynes serve on the Board of Directors.